Trump Cuts Prices on Ozempic and Wegovy in Deal With GLP-1 Weight Loss Drug Makers

President Trump has announced a significant reduction in the prices of the GLP-1 weight loss drugs, Ozempic and Wegovy, as part of a new deal with manufacturers Eli Lilly and Novo Nordisk. The monthly costs for these medications will be reduced to approximately $250, with future drugs capped at $149. Additionally, Medicare will begin covering these drugs for obesity, enabling eligible patients to pay a co-pay of around $50. The plan aims to enhance access to obesity treatments amid rising obesity rates, which are linked to increased healthcare costs. Trump highlighted that this initiative includes a federal purchasing option, dubbed “TrumpRX,” where consumers can buy GLP-1 medications directly from the government. The changes are expected to commence in mid-2026, benefiting around 10% of Medicare beneficiaries based on specific health criteria. The announcement has led to positive market trends for Eli Lilly and Novo Nordisk's stocks, reflecting investor optimism regarding the deal's potential impact on public health and affordability of essential medications.

Source 🔗